Asthma and COPD Drugs Market to Reach US$ 97.6 Bn by 2036, Driven by Combination Therapies, Biologics, and Digital Respiratory Care | Latest Report TMR

The global asthma and COPD drugs market is becoming an important segment of respiratory therapeutics as the number of patients requiring long-term disease management continues to rise. Valued at USD 44.7 billion in 2025, the market is projected to reach USD 97.6 billion by 2036, expanding at a CAGR of 7.5% from 2026 to 2036. Asthma and chronic obstructive pulmonary disease (COPD) require sustained treatment to control symptoms, prevent exacerbations, and reduce hospitalizations.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86923

The market includes bronchodilators, corticosteroids, combination inhalers, biologics, and mucolytics. Increasing disease prevalence, population ageing, tobacco exposure, air pollution, occupational hazards, and improved diagnosis are strengthening demand. At the same time, treatment is shifting from conventional inhaled medicines toward long-acting combinations, biologics, personalized therapies, and connected inhaler technologies.

Market Overview

The asthma and COPD drugs industry is supported by a large and expanding patient population across developed and emerging economies. Asthma affected about 363 million people in 2023, while COPD caused around 3.4 million deaths globally in the same year, highlighting the substantial burden of chronic respiratory disease.

North America dominated the market in 2025, accounting for 39.4% of global revenue. Strong healthcare infrastructure, high treatment rates, reimbursement availability, pharmaceutical innovation, and rapid adoption of advanced therapies support regional leadership. Asia Pacific is expected to offer significant long-term opportunities as healthcare investment, urbanization, diagnosis, and access to respiratory medicines improve.

By drug type, combination therapy held the largest share at 46.2% in 2025.

Key Drivers of Market Growth

Growing disease burden is the primary market driver. Ageing populations, smoking, outdoor air pollution, indoor biomass exposure, and occupational dust increase the prevalence and progression of respiratory disorders. COPD is particularly associated with long-term exposure to harmful particles and gases, while asthma affects both children and adults.

Expansion of the diagnosed population is another major factor. Improved primary-care awareness, spirometry access, screening, and disease recognition are converting previously undiagnosed patients into regular medicine users. This expands demand for maintenance inhalers, rescue medicines, combinations, and biologics.

Combination therapy is also reshaping treatment. In asthma, inhaled corticosteroid-containing therapies are increasingly favored over short-acting beta-agonist treatment alone. In COPD, LABA/LAMA and triple ICS/LABA/LAMA therapies are widely used for patients requiring greater symptom and exacerbation control. Single-inhaler approaches can simplify treatment and support adherence.

Key Players and Industry Leaders

The market is fragmented, with companies competing through product innovation, clinical development, and expansion. Leading participants include GSK, AstraZeneca, Boehringer Ingelheim, Sanofi, Regeneron Pharmaceuticals, Teva Pharmaceutical Industries, Chiesi Farmaceutici, Novartis, Roche, Amgen, Cipla, Viatris, Organon, Lupin, Orion Corporation, and others.

GSK maintains a strong respiratory position through its established inhaled portfolio and combination therapies. AstraZeneca benefits from a broad respiratory franchise spanning inhaled products and biologics. Sanofi and Regeneron have strengthened the severe-asthma biologics segment, while Boehringer Ingelheim, Teva, Chiesi, and regional manufacturers compete through inhaled medicines, delivery technologies, and generic alternatives.

Key Trends for the Future

The market is moving toward targeted biologics for patients with severe or uncontrolled disease. Longer dosing intervals, improved efficacy, and biomarker-driven treatment selection are increasing the role of precision medicine. Combination therapies are also becoming more sophisticated, particularly single-inhaler triple therapies.

Digital respiratory care is another trend. Connected inhalers can record medication use, monitor inhalation patterns, provide reminders, and help healthcare professionals identify adherence problems. Digital platforms can complement drug therapy by supporting continuous disease management and generating real-world evidence.

Explore our report to uncover in-depth insights - https://www.transparencymarketresearch.com/asthma-and-copd-drugs-market.html

New Opportunities and Challenges

Connected inhalers and digital respiratory-management platforms represent a strong opportunity. Pharmaceutical companies can combine medicines with monitoring technologies to improve adherence, differentiate products, and demonstrate reductions in exacerbations and healthcare utilization.

Emerging markets also offer substantial opportunities as healthcare infrastructure expands and diagnosis improves. However, high biologic prices, reimbursement restrictions, generic competition, regulatory requirements, and development costs remain important challenges. Pricing pressure may intensify as more inhaled products lose exclusivity.

Market Trends & Innovations

Innovation is focused on long-acting formulations, fixed-dose combinations, targeted biologics, and advanced inhaler delivery systems. In April 2026, AstraZeneca received U.S. FDA approval for BREZTRI AEROSPHERE as a fixed-dose triple-combination maintenance therapy for asthma in patients aged 12 years and older, expanding its established COPD use.

Generic competition is also influencing market dynamics. In July 2026, Cipla received U.S. FDA approval for generic Advair Diskus in three strengths, supporting broader access to established combination treatment.

Future Outlook

The global asthma and COPD drugs market is expected to maintain growth through 2036, supported by rising prevalence, ageing, better diagnosis, and innovation. Revenue growth will increasingly depend on combinations and biologics, while generics will expand access.

Market competition is likely to intensify as companies pursue new indications, improved delivery devices, longer dosing intervals, and personalized treatment. Digital health integration could further reshape disease management by connecting medicines, devices, and patient data.

Market Segmentation

The market is segmented by drug type, route, indication, combination type, channel, and region. Drug types include combination therapy, bronchodilators, corticosteroids, monoclonal antibodies, mucolytics, and others. Combination therapy includes ICS/LABA, ICS/LABA/LAMA, LABA/LAMA, and SABA/SAMA.

Routes include inhalation, oral, and parenteral administration. By indication, it includes asthma and COPD, with COPD further covering chronic bronchitis and emphysema. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Regional coverage includes North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

👉 To buy this comprehensive market research report, click here to inquire@ https://www.transparencymarketresearch.com/checkout.php?rep_id=86923<ype=S

Important FAQs with Answers

What is the asthma and COPD drugs market size?
The market was valued at USD 44.7 billion in 2025 and is projected to reach USD 97.6 billion by 2036.

What is the expected CAGR?
The market is projected to expand at a 7.5% CAGR from 2026 to 2036.

Which segment led the market in 2025?
Combination therapy led the drug type segment with a 46.2% share.

Which region dominated the market?
North America led with a 39.4% revenue share in 2025.

What are the major growth opportunities?
Key opportunities include biologics, single-inhaler combinations, connected inhalers, digital respiratory platforms, and expanding treatment access in emerging markets.

More Trending Reports by Transparency Market Research -

Natural APIs Market: https://www.transparencymarketresearch.com/natural-apis-market.html

PCSK9 Inhibitor Market: https://www.transparencymarketresearch.com/pcsk9-inhibitors-market.html

Neuroprotection Market: https://www.transparencymarketresearch.com/neuroprotection-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Sales Inquiries: sales@transparencymarketresearch.com
Media Inquiries: media@transparencymarketresearch.com

This release was published on openPR.